Abeona Therapeutics Inc

ABEONASDAQ · USD
2.60USD0.00 (+7.44%)
312

Abeona Therapeutics Inc (ABEO) Covered Calls

Read more

Running ABEO covered calls helps you generate income from Abeona Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ABEO covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ABEO stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ABEO covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ABEO covered call is worth writing.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs.

No illustrative rows to display.

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank67.86% Moderate
  • Market cap (M$)149
  • 52 weeks high-66.01%
  • 52 weeks low24.40%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$15.56
    498.46% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-11-09
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.11
  • EPS growth next 5 years—

As of Nov 16, 2026